BEMA Buprenorphine/Naloxone is now BDSI's lead drug program, Sirgo said. The treatment, indicated for treating opioid dependence, is the same drug combination provided by current market leader Suboxone, a $1 billion revenue product for Reckitt Benckiser (LON:RB). BDSI believes its proprietary drug delivery technology, which administers the drug via a small piece of film that dissolves when placed on the inside of the cheek, will offer it a competitive advantage and a $300 million chunk of the opioid dependence treatment market. BEMA Buprenorphine/Naloxone has a faster path to commercialization than BEMA Buprenorphine for chronic pain. Showing bioequivalence to the already approved and commercialized Suboxone means BDSI won't have to take its product through three phases of clinical trials. Bioequivalence studies, which will be funded from existing capital, are expected to begin in January.